・First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted available standard treatment options.

・Clinical activity observed in a heavily pretreated population: clinical activity was observed in a population with a median of four prior lines of therapy; 53% of patients had previously received CAR-T cell therapy and 60% CD3×CD20 bispecific antibodies.
READ FULL ARTICLE